EU OK's Lilly's Novartis animal health buy; Mylan ups 2014 guidance range;

@FiercePharma: Did you miss our latest special report yesterday? Not to worry: Top 10 pharma companies by employees - 2014. Report | Follow @FiercePharma

@CarlyHFierce: Salix drops Cosmo buy, opting to talk takeover with Actavis. More | Follow @CarlyHFierce

> The EU has approved Eli Lilly's ($LLY) acquisition of Novartis' ($NVS) animal health unit. More

> Mylan ($MYL) has increased its third quarter and full year 2014 adjusted diluted EPS guidance range. Release

> A federal judge in Newark, NJ, has remanded 57 cases concerning Sanofi ($SNY) and Bristol-Myers Squibb's ($BMY) Plavix to state court after rejecting claims that the plaintiffs fraudulently joined distributor McKesson ($MCK) to defeat diversity jurisdiction. More

> A California federal judge has remanded a wrongful death suit against AbbVie ($ABBV) over its AndroGel testosterone drug to state court, rejecting the company's bid to stay the suit while waiting for it to be transferred to the multidistrict litigation in Illinois over alleged injuries from testosterone treatments. More (sub. req.)

> Antibiotics use in livestock is rising, the FDA has found. More (sub. req.)

> LEO Pharma's Taclonex Topical Suspension has won an indication to treat scalp plaque psoriasis in pediatric patients ages 12-17. Release

Medical Device News

@FierceMedDev: Have you checked out our 15 most promising #medtech companies yet? Report | Follow @FierceMedDev

@VarunSaxena2: Alnylam says it wants to enter larger disease areas using partnership-driven approach. News | Follow @VarunSaxena2

@EmilyWFierce: FDA cracking down on companies marketing essential oils as treatments or cures for Ebola. More from the WSJ | Follow @EmilyWFierce

> Hopkins physician creates 3-D printed hands for pediatric patients. More

> EU regulators to conduct antitrust probe of $13.4B Zimmer/Biomet deal. Story

> Glooko enables wireless smartphone access for existing blood glucose monitors. News

Biotech News

@FierceBiotech: IPO hopeful rEVO puts off its plans for a $75M debut. Item | Follow @FierceBiotech

@JohnCFierce: Interesting to see which #biotech #IPOs do well and which flop. Congrats to $DERM. | Follow @JohnCFierce

@DamianFierce: ICYMI: $LLY's bailing on tabalumab­ in lupus after two Phase III misses. Release | Follow @DamianFierce

@EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. | Follow @EmilyMFierce

> Report: Arbor Pharma goes on the block for $1B-plus. Story

> EMA adopts open trial data policy to begin Jan. 1. Article

> Dermira pulls off a $125M IPO as biotechs wax and wane on Wall Street. News

And Finally... Overprescribing of painkillers is fueling nearly 17,000 annual deaths from overdoses in the United States as well as a rise in heroin use, a new CDC study says. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.